MATCHING-ADJUSTED INDIRECT COMPARISON OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR

Autor: O Al-Sawaf, M Jen, LM Hess, J Zhang, B Goebel, JM Pagel, TA Eyre, LYCGN Presenter

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S162- (2023)

Objectives: Venetoclax-based therapy is a standard option for pts with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) previously treated with a covalent BTK inhibitor (cBTKi). Pirtobrutinib is a highly selective, non-covalent (reversibl

Externí odkaz: https://doaj.org/article/7d318f13915c476ba6fcf0221626f667

PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH 2 YEARS OF SURVIVAL FOLLOW-UP

Autor: NN Shah, PL Zinzani, TA Eyre, K Izutsu, AJ Alencar, K Patel, T Munir, DE Tsai, ML Wang, LYGN Presenter

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S359-S360 (2023)

Objectives: Pirtobrutinib is a highly selective, non-covalent (reversible) BTK-inhibitor (BTKi). Here, we report updated results of pirtobrutinib in patients (pts) with cBTKi pre-treated relapsed/refractory (R/R) mantle cell lymphoma (MCL) and more t

Externí odkaz: https://doaj.org/article/ea5cab8ac016489bb129b25fbcfe30f2

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.

Autor: Shah NN; Medical College of Wisconsin, Milwaukee, WI. nishah@mcw.edu., Wang M; MD Anderson Cancer Center, Houston, TX., Roeker LE; Memorial Sloan Kettering Cancer Center, New York, NY., Patel K; Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy, Seattle, WA., Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Wierda WG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Ujjani CS; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA., Eyre TA; Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford., Zinzani PL; Institute of Hematology 'Seragnoli' University of Bologna, Bologna., Alencar AJ; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL., Ghia P; Universita Vita-Salute San Raffaele, Milano, Italy; IRCCS Ospedale San Raffaele, Milano., Lamanna N; New York-Presbyterian Columbia University Medical Center, New York, NY., Hoffmann MS; Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL., Flinn I; Sarah Cannon Research Institute, Nashville, TN., Gerson JN; Lymphoma Program, Abramson Cancer Center, Philadelphia, PA., Ma S; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL., Coombs CC; University of California Irvine, Irvine, CA., Cheah CY; Linear Clinical Research and Sir Charles Gairdner Hospital, Perth., Lech-Maranda E; Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Fakhri B; Division of Hematology at Stanford University School of Medicine, Stanford, CA., Kim WS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul., Barve MA; Mary Crowley Cancer Research Center, Dallas, TX., Cohen JB; Winship Cancer Institute, Emory University, Atlanta, GA., Jurczak W; Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland., Munir T; Department of Haematology, St. James's University Hospital, Leeds., Thompson MC; Memorial Sloan Kettering Cancer Center, New York, NY., Tsai DE; Loxo@Lilly, Indianapolis, IN., Bao K; Loxo@Lilly, Indianapolis, IN., Cangemi NA; Loxo@Lilly, Indianapolis, IN., Kherani JF; Loxo@Lilly, Indianapolis, IN., Walgren RA; Loxo@Lilly, Indianapolis, IN., Han H; Loxo@Lilly, Indianapolis, IN., Ruppert AS; Eli Lilly and Company, Indianapolis, IN., Brown JR; Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

Publikováno v: Haematologica [Haematologica] 2024 Oct 03. Date of Electronic Publication: 2024 Oct 03.

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.

Autor: Malinverni C; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy., Bernardelli A; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy., Glimelius I; Department of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University, Uppsala, Sweden., Mirandola M; Epidemiology Unit, Division of Infectious Diseases, Department of Medicine, World Health Organization Collaborating Centre for Sexual Health and Vulnerable Populations, Verona University Hospital, Verona, Italy.; School of Health Sciences, University of Brighton, Brighton, United Kingdom., Smedby KE; Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Solna, Sweden.; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden., Tisi MC; Department of Hematology and Cell Therapy, San Bortolo Hospital, Vicenza, Italy., Giné E; Department of Hematology, Hospital Clinic of Barcelona, Barcelona, Spain., Albertsson-Lindblad A; Department of Oncology, Skane University Hospital, Lund, Sweden., Marin-Niebla A; Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain., Di Rocco A; Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Moita F; Department of Hematology, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal., Sciarra R; Division of Hematology, Fondazione IRCSS Policlinico San Matteo, Pavia, Italy., Bašić-Kinda S; Division of Hematology, University Hospital Centre, Zagreb, Croatia., Hess G; Department of Hematology, Oncology, and Pneumology, Comprehensive Cancer Center, Johannes Gutenberg University, Mainz, Germany., Ohler A; Department of Hematology, Oncology, and Pneumology, Comprehensive Cancer Center, Johannes Gutenberg University, Mainz, Germany., Eskelund CW; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Re A; Division of Hematology, Spedali Civili di Brescia, Brescia, Italy., Ferrarini I; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy., Kolstad A; Department of Oncology, Sykehuset Innlandet, Lillehammer, Norway., Räty R; Department of Hematology, Helsinki University Hospital, Helsinki, Finland., Quaglia FM; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy., Eyre TA; Department of Clinical Hematology, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom., Scapinello G; Division of Hematology and Clinical Immunology, Department of Medicine, University of Padua, Padua, Italy., Stefani PM; Division of Hematology, Treviso Regional Hospital, Treviso, Italy., Morello L; Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Milan, Italy., Nassi L; Division of Hematology, Careggi Hospital and University of Florence, Florence, Italy., Hohaus S; Department of Radiological and Hematological Sciences, Catholic University of the Sacred Heart, Rome, Italy., Ragaini S; Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy., Zilioli VR; Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy., Bruna R; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont Amedeo Avogadro, Novara, Italy., Cocito F; Division of Hematology, San Gerardo Hospital, Monza, Italy., Arcari A; Division of Hematology, Ospedale Guglielmo da Saliceto, Piacenza, Italy., Jerkeman M; Department of Oncology, Lund University Hospital, Lund, Sweden., Visco C; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.

Publikováno v: Blood [Blood] 2024 Aug 29; Vol. 144 (9), pp. 1001-1009.

Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.

Autor: Lim YJ; Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK., Ward V; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Department of Medical Microbiology and Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Brown A; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Phillips E; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Kronsteiner B; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Malone T; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Jennings D; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Healy S; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Longet S; Nuffield Department of Medicine, University of Oxford, Oxford, UK., James T; Department of Clinical Biochemistry, John Radcliffe Hospital, Oxford, UK., Thomson P; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, UK., Farrell L; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, UK., Oates M; Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK., Jackson R; Department of Health Data Science, University of Liverpool, Liverpool, UK., Morrison A; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK., Burns M; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK., Carroll M; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Klenerman P; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Turtle L; Department of Clinical Infection, Microbiology & Immunology, University of Liverpool, Liverpool, UK., Naisbitt D; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, UK., Rhodes M; National Cancer Research Institute Consumer Forum, London, UK., Robinson K; National Cancer Research Institute Consumer Forum, London, UK., Gatto S; Cardiff and Vale University Hospitals Board, Cardiff, UK., Young M; East Kent Hospitals University NHS Foundation Trust, Ashford, UK., Linton K; University of Manchester, Manchester, UK.; The Christie NHS Foundation Trust, Manchester, UK., Eyre TA; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Eyre DW; Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Dunachie S; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Barnes E; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Pettitt A; Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Aug; Vol. 205 (2), pp. 440-451. Date of Electronic Publication: 2024 Jun 13.